702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

Bibliographic Details
Main Authors:	Wenqing Jiang, Zhengyi Wang, Jaeho Jung, Zhen Sheng, Taylor Guo
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer
by: Ke Xu, et al.
Published: (2023-11-01)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
by: Xi Chen, et al.
Published: (2023-06-01)

283 Preclinical development and characterization of allogeneic CAR T cells targeting Claudin18.2-positive tumors
by: Zhe Li, et al.
Published: (2023-11-01)

845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade
by: Seung Hyuck Jeon, et al.
Published: (2023-11-01)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
by: Hayat Bähr-Mahmud, et al.
Published: (2023-12-01)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
by: Weijie Cao, et al.
Published: (2022-05-01)

Claudin18.2 in Advanced Gastric Cancer
by: Rin Inamoto, et al.
Published: (2023-12-01)

Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression
by: Shengde Liu, et al.
Published: (2024-01-01)

1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile
by: Matthew Zhou, et al.
Published: (2023-11-01)

Correlation analysis of circulating tumor cells and Claudin-4 in breast cancer
by: Jie Chai, et al.
Published: (2023-07-01)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
by: Hongtai Shi, et al.
Published: (2023-07-01)

Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
by: Yohei Kubota, et al.
Published: (2024-01-01)

Dawn of Targeted Therapy Using Claudin18.2 for Gastric Cancer
by: LI Hao, et al.
Published: (2023-10-01)

Targeting 4-1BB for tumor immunotherapy from bench to bedside
by: Ya-Tao Wang, et al.
Published: (2022-09-01)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
by: Bo Xu, et al.
Published: (2022-06-01)

High Expression of Claudin-4 Is Associated with Synchronous Tumors in Patients with Early Gastric Cancer
by: Won Shik Kim, et al.
Published: (2022-06-01)

659 Repeated dosing of anti-Claudin 18.2 CAR-T in metastatic gastrointestinal cancer
by: Dan Zhao, et al.
Published: (2023-11-01)

Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer
by: Qian Xu, et al.
Published: (2024-03-01)

7.02 / 10.702 Experimental Biology & Communication, Spring 2005
by: King, Jonathan, et al.
Published: (2023)

1192 A novel MSLN×4–1BB bispecific antibody for solid tumor
by: Guodong Shen, et al.
Published: (2023-11-01)

Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
by: Maria Cecília Mathias-Machado, et al.
Published: (2024-02-01)

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells
by: Gregory A Daniels, et al.
Published: (2024-02-01)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
by: Changsong Qi, et al.
Published: (2023-09-01)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
by: Hyung-Don Kim, et al.
Published: (2023-11-01)

KS. KAZIMIERZ DRZYMAŁA TJ, Ks. Marcin Śmiglecki TJ, Kraków 1981
by: Jerzy Chmiel
Published: (1983-02-01)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
by: Weixiang Zhong, et al.
Published: (2022-06-01)

738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
by: Daniel J Olson, et al.
Published: (2023-11-01)

Imaging of claudin-4 in pancreatic ductal adenocarcinoma using a radiolabelled anti-claudin-4 monoclonal antibody
by: Torres, J, et al.
Published: (2017)

1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing
by: Rakesh Kumar, et al.
Published: (2023-11-01)

T.J. - S.D.
by: Fiamma Montezemolo
Published: (2003-12-01)

The Text-Justifier TJ6
by: Greenblatt, R., et al.
Published: (2004)

The Text-Justifier TJ6
by: Cohen, Joseph D.
Published: (2004)

Murine mammary tumor cells with a claudin-low genotype
by: Siwicky Megan D, et al.
Published: (2011-08-01)

Claudin-4 localization in epithelial ovarian cancer
by: Margaret C. Neville, et al.
Published: (2022-10-01)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
by: Shiyu Liu, et al.
Published: (2023-09-01)

Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2
by: Weijun Wei, et al.
Published: (2022-12-01)

P182: Adverse outcome in FAM111A variant: A case report
by: Katherine Guilbo, et al.
Published: (2023-01-01)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
by: Yichen Wang, et al.
Published: (2022-12-01)

Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity.
by: Li, J, et al.
Published: (2010)

235 Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers
by: Mark Cobbold, et al.
Published: (2023-11-01)